Pfizer (PFE) Net Cash Flow Growth (3y) (2012 - 2026)
Pfizer (PFE) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 38.95% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -49.89% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 33.59% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 37.67% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -129.17% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -10.13% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -98.96% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -51.84% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 8.91% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -68.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -51.84% |
| Mar 29, 2026 | -32.34% |
| Jun 29, 2025 | 31.57% |
| Mar 30, 2025 | -10.34% |
| Sep 29, 2024 | -71.48% |
| Jun 30, 2024 | -15.89% |
| Mar 31, 2024 | -408.92% |
| Jul 2, 2023 | -63.94% |
| Apr 2, 2023 | 171.07% |
| Jul 3, 2022 | -63.71% |
| Apr 3, 2022 | -12.12% |
| Oct 3, 2021 | -15.73% |
| Jul 4, 2021 | 9.17% |
| Apr 4, 2021 | -26.35% |
| Sep 27, 2020 | 23.56% |
| Jun 28, 2020 | 107.21% |
| Mar 29, 2020 | -27.40% |
| Dec 31, 2019 | -134.25% |
| Sep 29, 2019 | 40.67% |
| Jun 30, 2019 | -29.42% |